newsfilter
← Latest News
GlobeNewswire·

Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates

- Completed Type C meeting with FDA to align on study design, study population, control group and primary endpoint for planned Phase 3 essential thrombocythemia (ET) study - Enrollment completed in Phase 2 trial of bomedemstat for treatment of ET